Company
DotBioHK Limited (“DotBioHK”) is a Hong Kong-based, wholly-owned subsidiary of DotBio Pte Ltd (DotBio), a Singapore-based biopharmaceutical start-up focusing on next-generation multi-specific antibody drugs. DotBio has a proprietary humanized, stable Domain Therapeutic Antibody (“Dotbody”) technology that will revolutionize multi-specific therapies, antibody-drug conjugates and CAR-T therapies. DotBio currently possesses proprietary state-of-art DotBody and Fab phage display libraries, as well as numerous pre-clinical assets in the immune-oncology field. Meanwhile, DotBioHK will have a major focus on non-oncology therapeutic areas.
Technology
DotBio’s proprietary DotBody technology platform is based on the concept of modular design. By prefabricating antibody modules with specific functions, DotBio is able to combine them on demand to build multi-functional antibodies. This high throughput process allows DotBio to generate bi- and tri-specific antibodies, antibody-drug conjugates (ADCs) and intracellular antibodies in a matter of months.
